AIMC Topic: Antineoplastic Agents

Clear Filters Showing 431 to 440 of 592 articles

Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid Leukemia.

Clinical lymphoma, myeloma & leukemia
BACKGROUND: Monitoring renal function is important in imatinib-treated patients with chronic myeloid leukemia because serum creatinine may increase during the course of therapy. The mechanism of this increase and its reversibility on treatment cessat...

Predicting target proteins for drug candidate compounds based on drug-induced gene expression data in a chemical structure-independent manner.

BMC medical genomics
BACKGROUND: Phenotype-based high-throughput screening is a useful technique for identifying drug candidate compounds that have a desired phenotype. However, the molecular mechanisms of the hit compounds remain unknown, and substantial effort is requi...

Adjuvant Carboplatin Treatment in 115 Patients With Stage I Seminoma: Retrospective Multicenter Survey.

Clinical genitourinary cancer
BACKGROUND: The administration of carboplatin AUC 7 has become a standard adjuvant option for patients undergoing orchiectomy for stage I seminoma, in alternative to radiotherapy on retroperitoneal lymphnodes or surveillance. The toxicity of AUC 7 ca...

canSAR: an updated cancer research and drug discovery knowledgebase.

Nucleic acids research
canSAR (http://cansar.icr.ac.uk) is a publicly available, multidisciplinary, cancer-focused knowledgebase developed to support cancer translational research and drug discovery. canSAR integrates genomic, protein, pharmacological, drug and chemical da...

tcTKB: an integrated cardiovascular toxicity knowledge base for targeted cancer drugs.

AMIA ... Annual Symposium proceedings. AMIA Symposium
Targeted cancer drugs are often associated with unexpectedly high cardiovascular (CV) adverse events. Systematic approaches to studying CV events associated with targeted anticancer drugs have high potential for elucidating the complex pathways under...

A Tool for Predicting Regulatory Approval After Phase II Testing of New Oncology Compounds.

Clinical pharmacology and therapeutics
We developed an algorithm (ANDI) for predicting regulatory marketing approval for new cancer drugs after phase II testing has been conducted, with the objective of providing a tool to improve drug portfolio decision-making. We examined 98 oncology dr...

Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning.

Molecular oncology
Increasingly, the effectiveness of adjuvant chemotherapy agents for breast cancer has been related to changes in the genomic profile of tumors. We investigated correspondence between growth inhibitory concentrations of paclitaxel and gemcitabine (GI5...

Inferring Association between Compound and Pathway with an Improved Ensemble Learning Method.

Molecular informatics
Emergence of compound molecular data coupled to pathway information offers the possibility of using machine learning methods for compound-pathway associations' inference. To provide insights into the global relationship between compounds and their af...

[Implementation of a robot for the preparation of antineoplastic drugs in the Pharmacy Service].

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria
OBJECTIVE: To describe the implementation of a robot for the preparation of antineoplastic drugs in the Pharmacy Service and to be able to analyze the added value to pharmacotherapy.